Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.45 |
| ▸ | METAP2 | P50579 | 2/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22853159 | 1.00 | FABP3 (0.47) | FABP3FABP4CLCN2METAP2FTO | |
| SCHEMBL30294488 | 0.88 | SMN1; SMN2 (0.45) | P2RX7PKMSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22853407 | 0.88 | SMN1; SMN2 (0.45) | P2RX7PKMSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL30294242 | 0.85 | FABP3 (0.51) | FABP3FABP4CLCN2METAP2FTO | |
| SCHEMBL22853097 | 0.85 | FABP3 (0.51) | FABP3FABP4CLCN2METAP2FTO | |
| SCHEMBL22853082 | 0.84 | CLCN2 (0.53) | FABP3FABP4CLCN2FTOMPO | |
| SCHEMBL30294669 | 0.84 | CLCN2 (0.53) | FABP3FABP4CLCN2FTOMPO | |
| SCHEMBL22853345 | 0.84 | KDM4E (0.51) | FABP3FABP4METAP2MPOMAPT | |
| SCHEMBL22853459 | 0.81 | FABP3 (0.46) | FABP3FABP4CLCN2FTOMPO | |
| SCHEMBL30294786 | 0.81 | FABP3 (0.46) | FABP3FABP4CLCN2FTOMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | FABP3 2946/4885FABP4 4623/4885CLCN2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.